Technology
Engineered to
redefine toxins
Recombinant Botulinum Neurotoxin
A scalable recombinant botulinum toxin production platform enabling rapid and safe engineering through recombinant expression.
Recombinant BoNT(rBoNT)
Conventional botulinum toxin(BoNT) products have faced inherent limitations due to their reliance on naturally occurring strains of Clostridium botulinum strains for production. MVRIX overcomes these constraints by producing botulium toxin using E. coli as a host strain, unlocking the full and virtually unlimited potential of botulinum Toxin.
Conventional BoNT
Difficulty securing strains with desired properties
Classfied High-risk biological agent, requiring strict safety control
Limited flexibility for structural and functional modification
Conventional botulinum toxin products are produced only from naturally occurring strains of Clostridium botulinum. However, such strains are extremely rare in nature, and securing diverse types suitable for pharmaceutical use remains an even greater challenge.
Recombinant BoNT
Flexible strain origin, easier IP protection
Safe and rapid production process
Engineering-driven performance enhancement
Recombinant botulinum neurotoxins ensure high safety through an E. coli–based production process and enable diverse performance enhancements through precise engineering.
Advantages
Core toxins resistant to immunity
Core toxins can be produced quickly and safely without inducing resistance.
Improved botulinum toxins
Botulinum toxins can be developed with faster onset and longer duration of action.
Domain engineering
By engineering different domains of botulinum toxins, their indications can be expanded.
Improved
Production system
-
We use E. coli as the host to eliminate the risk of strain disputes and to produce core toxins with a very low likelihood of resistance.
-
The recombinant production process improves safety and maximizes efficiency by shortening production timelines.
Overexpression
Broader Application
Various serotypes can be produced in E. coli, and with our engineering techniques, they can be adapted to a wide range of indications, from aesthetic use to medical applications.
Botulinum toxin consists of three core domains: LC, Hn, and Hc.
R&D Achievements
Discover the intellectual property activities we are pursuing around rBoNT.
Filed
KR
10/21/25
Filed
FGF-BoNT fusion protein in which FGF protein and BoNT protein are fused, and a cosmetic composition comprising the same
Filed
PCT
3/6/25
Filed
Method for producing botulinum toxin using soluble partner and intein
Filed
KR
10/24/24
Filed
FGF-BoNT fusion protein in which an FGF protein and a BoNT protein are fused, and a cosmetic composition comprising the same
Filed
PCT
4/17/22
Filed
Protein complex including botulinum toxin translocation domain and endolysin and antibacterial composition including same
Filed
IN
2/21/22
Filed
Method for safely producing botulinum neurotoxin
Filed
PCT
12/17/20
Filed
Method for safely producing botulinum neurotoxin
10-2790255
KR
3/28/25
Granted
Recombinant botulinum toxin and pharmaceutical compositions containing the same
12,171,814
US
12/24/24
Granted
Protein complex including botulinum toxin translocation domain and endolysin and antibacterial composition including same
12,171,815
US
12/24/24
Granted
Method for safely producing botulinum neurotoxin
10-2731131
KR
11/12/24
Granted
Method for Producing botulinum neurotoxin using soluble partner and GP41.1 intein
ZL 202080059073.1
CN
8/6/24
Granted
Safe preparation of botulinum neurotoxin
10-2610179
KR
11/30/23
Granted
A method for safe production of botulinum neurotoxin
10-2597062
KR
10/27/23
Granted
A method for safe production of botulinum neurotoxin using 3-part fragment production
10-2547393
KR
6/20/23
Granted
Protein Complex Comprising Botulinum Toxin Translocation Domain and Endolysin, and Anti-Bacterial Composition Comprising Thereof
출원
KR
12/9/25
출원
Hc와 Hn 도메인 사이에 인터도메인 링커가 삽입된 재조합 보툴리눔
출원
PCT
11/13/25
출원
재조합 보툴리눔 독소 및 이를 함유하는 약학 조성물